Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.78 |
| ▸ | MIF | P14174 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | CASP1 | P29466 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | PDE4A | P27815 | 4/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18279371 | 0.99 | USP2 (0.76) | USP2MIFNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17003822 | 0.91 | PDE4A (0.78) | USP2MIFNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17010357 | 0.90 | TSHR (0.78) | USP2MIFNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17003763 | 0.90 | PDE4A (0.77) | USP2MIFNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17003843 | 0.83 | PDE4B (0.73) | USP2MIFNPC1RAB9AALDH1A1 | |
| SCHEMBL17003880 | 0.83 | PDE4D (0.73) | USP2MIFNPC1RAB9AALDH1A1 | |
| SCHEMBL7399375 | 0.81 | MIF (1.00) | MIFSMN1; SMN2ALDH1A1PDE4APDE4B | |
| SCHEMBL17003858 | 0.78 | PDE4D (0.72) | USP2MIFALDH1A1TSHRPDE4A | |
| SCHEMBL18288878 | 0.77 | PDE4A (0.56) | USP2NPC1RAB9ASMN1; SMN2CASP1 | |
| SCHEMBL18288875 | 0.76 | PDE4A (0.56) | USP2NPC1RAB9ASMN1; SMN2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3105206-B1 | MORPHOLINE DERIVATIVES HAVING A SELECTIVE PDE4D INHIBITING ACTIVITY | UNIV DEGLI STUDI GENOVA (IT) | 2019-08-07 | — | — | EP | disclosed |
| US-10017480-B2 | Compounds having a selective PDE4D inhibiting activity | UNIVERSITA DEGLI STUDI DI GENOVA (IT) | 2018-07-10 | — | — | US | disclosed |
| EP-3105206-A1 | NEW COMPOUNDS HAVING A SELECTIVE PDE4D INHIBITING ACTIVITY | Universita' degli Studi di Genova (IT) | 2016-12-21 | — | — | EP | disclosed |
| US-20160355489-A1 | NEW COMPOUNDS HAVING A SELECTIVE PDE4D INHIBITING ACTIVITY | THE TRUSTEES OF COLUMBIA UNIVERSITY | 2016-12-08 | — | — | US | disclosed |
| WO-2015121212-A1 | NEW COMPOUNDS HAVING A SELECTIVE PDE4D INHIBITING ACTIVITY | UNIVERSITÀ DEGLI STUDI DI GENOVA (IT) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355489-A1 | NEW COMPOUNDS HAVING A SELECTIVE PDE4D INHIBITING ACTIVITY | PDE4A, PDE4D, PDE4B | USP2 963/4885MIF 4228/4885NPC1 1531/4885 |
| US-10017480-B2 | Compounds having a selective PDE4D inhibiting activity | PDE4A, PDE4D, PDE2A | USP2 1110/4885MIF 4248/4885NPC1 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.